ArticleMolecular cancer therapeutics2017
Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 78 citations in OpenAlex.
- Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.Cancer letters · 2026Article
- Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.BMC cancer · 2026Article
- RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.International journal of molecular sciences · 2026Review
- How to manage medullary thyroid carcinoma: current treatment strategies.Drugs in context · 2026Review
- Activation of the AKT-mTOR pathway confers selpercatinib resistance in thyroid cancer cells harboring theBiochemistry and biophysics reports · 2025Article
- Systemic Therapies for Advanced Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.Molecular oncology · 2024Article
- MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.Molecular cancer therapeutics · 2024Article
- Case report: Intrapleural plus systemic Tislelizumab injection combined chemotherapy in RET gene fusion-positive lung adenocarcinoma presenting refractory malignant pleural effusion.Frontiers in oncology · 2024Article
- Article
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.Thoracic cancer · 2023Article
- Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Cancer research · 2023Article
- A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes.Biology open · 2023Article
- SOS2 regulates the threshold of mutantbioRxiv : the preprint server for biology · 2023Article
- A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes.bioRxiv : the preprint server for biology · 2023Article
- The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.Journal of cancer research and clinical oncology · 2023Article
- Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.Frontiers of medicine · 2023Review
- Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Sarah K Nelson-TaylorDivision of Medical Oncology, or.
Anh T LeDivision of Medical Oncology, or.
Minjae YooDivision of Medical Oncology, or.
Laura SchubertDivision of Medical Oncology, or.
Katie M MishallDivision of Endocrinology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Andrea DoakDivision of Medical Oncology, or.
Marileila Varella-GarciaDivision of Endocrinology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Aik-Choon TanDivision of Medical Oncology, or.
Robert C DoebeleDivision of Medical Oncology, or robert.doebele@ucdenver.edu.
University of Colorado Denver · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MTissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8MTraining Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5MThe role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.R01CA193935 · NCI · UNIVERSITY OF COLORADO DENVER · PI DOEBELE, ROBERT C · 2016 to 2020
$2.0MCombinatorial microRNA signaling in melanomaF30CA171713 · NCI · UNIVERSITY OF COLORADO DENVER · PI NELSON-TAYLOR, SARAH K · 2012 to 2016
$151kNCI NIH HHS F30 CA171713NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA058187NCI NIH HHS R01 CA193935NCI NIH HHS T32 CA190216
Abstract
Oncogenic rearrangements in
Indexed as
Drug Resistance, NeoplasmMAP Kinase Signaling SystemAxl Receptor Tyrosine KinaseCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationErbB ReceptorsGene RearrangementGTP PhosphohydrolasesHumansImidazolesLung NeoplasmsMembrane ProteinsMutationOncogenesPhosphatidylinositol 3-KinasesAXL protein, humanAxl Receptor Tyrosine KinaseErbB ReceptorsGTP PhosphohydrolasesImidazolesMembrane ProteinsNRAS protein, humanPhosphatidylinositol 3-KinasesponatinibProto-Oncogene ProteinsProto-Oncogene Proteins c-retPyridazinesReceptor Protein-Tyrosine KinasesRET protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.